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Abstract
Background: Molecular studies of appendage regeneration have been hindered by the lack of a stable and
efficient means of transferring exogenous genes. We therefore sought an efficient integrating virus system that
could be used to study limb and tail regeneration in salamanders.
Results: We show that replication-deficient foamy virus (FV) vectors efficiently transduce cells in two different
regeneration models in cell culture and in vivo. Injection of EGFP-expressing FV but not lentivirus vector particles
into regenerating limbs and tail resulted in widespread expression that persisted throughout regeneration and
reamputation pointing to the utility of FV for analyzing adult phenotypes in non-mammalian models. Furthermore,
tissue specific transgene expression is achieved using FV vectors during limb regeneration.
Conclusions: FV vectors are efficient mean of transferring genes into axolotl limb/tail and infection persists
throughout regeneration and reamputation. This is a nontoxic method of delivering genes into axolotls in vivo/
in vitro and can potentially be applied to other salamander species.
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Background
Limb regeneration of salamanders has fascinated scien-
tists for several decades. Salamanders, Newts and
Axolotls, are used as model animals in limb regeneration
studies. Regeneration of missing structures is achieved
by blastema, a pool of restricted progenitors that is
formed after amputation [1].
Electroporation of DNA is the fastest and efficient
method to introduce exogenous transgenes into salamander
limb and spinal cord in vivo but this expression is lost dur-
ing regeneration as the electroporated DNA is episomal [2].
Infection of cells both in cell culture and in vivo by
modified viruses has been a powerful means of express-
ing exogenous genes in various experimental systems.
For example, retroviral infection has been crucial for the
molecular analysis of chicken limb development [3]. A
corresponding molecular analysis of limb regeneration
in salamanders has been limited due to a paucity in gene
transduction methods. Vaccinia and adenovirus have
been used in limb regeneration studies, but their toxicity
and non-integration phenotype limits their effectiveness
[4,5]. Similarly, pseudotyped retroviruses have been used
in cultured cells [5-7] and a recent report showing their
use in vivo but the issue of viral silencing after second
round of regeneration was not investigated [8]. We
therefore sought a virus system that efficiently and stably
infects salamander cells in vitro and in vivo and does
not require pseudotyping and is not prone to silencing
during initial and second round of regeneration.
Foamy viruses (FV) are a special type of retroviruses that
are endemic to most non-human primates, horses, cattle
and cats [9]. They were only lately successfully introduced
into the repertoire of vector systems for the correction of
inherited diseases, in particular of the hematopoietic
lineage, in the mammalian system [10,11]. However, they
have proven to be an efficient, non-toxic and stably
integrating gene delivery vector system for mammalian
cells. Some of their unique features, including their appa-
rent apathogenicity, infectious particle-associated DNA
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genome, extremely broad host range as well as their effi-
cient transduction capability for hematopoietic stem cells
(HSC), make them one of the most promising tools for
various gene therapeutic approaches [11].
One hallmark of FVs is their extremely broad tropism,
including even very distantly related organisms as
reptiles or birds [12,13]. The nature of the broadly
expressed, and potentially evolutionary conserved, cellu-
lar receptor(s) of FV glycoprotein-mediated attachment
and entry remains poorly characterized. Though, several
lines of evidence from recent publications suggest that
proteoglycans and heparin sulfate function particularly
as important attachment factors for FV Env-mediated
host cell infection, additional uncharacterized molecules
appear to be essential for fusion of viral and cellular lipid
membranes during uptake of virions [14,15]. Based on
this feature we tested whether salamander cells would be
transduced by FV vectors in vitro and in vivo. We also
compared their transduction profile to that of lentiviral
(LV) vectors pseudotyped with the vesicular stomatitis
virus glycoprotein G (VSV-G), which has gained favor in
gene delivery methods [16].
Results and discussion
To test and compare transduction efficiencies of Foamy
virus (FV) and Lentivirus (LV) vectors in salamanders,
FV and LV vector particles were generated by transient
transfection of 293T cells with transfer vectors (PV, LV)
containing an identical human ubiquitin C (UBIC) pro-
moter driven EGFP marker gene cassette including a
WPRE posttranscriptional element, and the correspond-
ing packaging expression constructs (PE, PP, PG; LG/P,
VG) (Figure 1A, B). We first tested the infectability of
cultured cell lines derived from the newt and the axolotl
limb [5,17]. Target cells were exposed to vector particles
at a titer of 1.74x106 IU/ml (FV and LV) for 8 hours with
an MOI (multiplicity of infection) of 130 and analyzed
in weekly intervals by FACS analysis for the percentage
of EGFP-positive cells (Figure 1C). In one week, the
newt and axolotl cells undergo approximately two dou-
blings. One week after viral transduction, both the
LV- and FV-transduced cells showed close to 50% GFP-
expressing cells. By four weeks, the FV-transduced cell
preparation showed close to 75% EGFP-expressing cells
and remained stably at this level over 11 weeks in cul-
ture. In contrast, the LV-transduced cells decreased sta-
bly to 20% EGFP-expressing cells. Furthermore, using
higher concentration/titer of viruses or different ratios
of vector particles to target cells, a similar decline in LV
infectivity was observed suggesting that the decline/inef-
ficiency of LV infection cannot be circumvented by using
more infectious particles (data not shown).
Figure 2 shows fluorescence images of EGFP expres-
sing newt (Figure 2A-D) and axolotl cell cultures
Figure 1 Foamy virus displays high efficiency of transduction with stable expression in cultured newt cells. A+B) Schematic outline of
the FV (A) and lentiviral (B) vector systems used. FV or LV components are indicated in grey, heterologous transcriptional control elements in
black, and the transgene and posttranslational control element in white. C) The Newt myogenic cell line A1, was transduced with FV (FV/FV, solid
squares) or LV (HIV/VSV-G, solid circles) vector particles expressing a hUbiC promoter-driven EGFP transgene at a MOI of 130. In weekly intervals
the percentage of EGFP expressing cells was determined by flow cytometry. The initial rate of expression was similar for both viruses but FV
transduced cells increased over time, plateauing at 3 weeks post-infection at approximately 75% expressing cells. In contrast, a large number of
LV transduced cells lost expression after initial infection and plateaued at 20% expressing cells. PFV based transfer vector (PV) and packaging
constructs for PFV glycoprotein (PE, ENV), PFV polymerase (PP, POL) and PFV capsid (PG, GAG); HIV-1 based transfer vector (LV) and packaging
constructs for HIV-1 capsid (GAG) and polymerase (POL) (LG/P) and VSV glycoprotein (VG, VSV-G). CMV: cytomegalo virus immediate early
enhancer – promoter; R: long terminal repeat (LTR) repeat region; U5: LTR unique 5’ region; ΔU3: enhancer-promoter deleted LTR unique 3’
region; CASI+II: FV cis-acting sequences I and II; hUbiC: human ubiqutin C promoter; WPRE: Woodchuck hepatitis virus posttranscriptional
regulatory element; : HIV-1 packaging sequence; RRE: rev-responsive-element; cPPT: central poly purine tract; SD: splice donor; SA: splice acceptor.
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(Figure 2E-H) at 21 days post transduction with FV and
LV vectors. The reason for the initial decline in the
number of EGFP-positive cells in samples transduced
with LV vectors and increase in FV vector transduced
samples within the first three weeks post transduction is
currently unclear. A silencing of integrated LV vector
genomes and not FV vector genomes in individual cells
is one possible explanation. Alternatively, it might be the
result of the differential capability of LV and FV vectors
to integrate their reverse transcribed genomes in inter-
phase chromatin. The LV vector derived initial high
number of EGFP expressing cells can be a consequence
Figure 2 Foamy virus vectors transduce both newt and axolotl cell cultures. Newt A1 (A-D) and Axolotl blastema (E-H) cells were infected
with FV and LV vectors encoding EGFP and epifluorescence images taken 3 weeks post-transduction. A. Uninfected newt cells. B. FV infected
newt cells. C. LV infected newt cells. D. Phase contrast image of culture from C. E. Uninfected axolotl cells. F. FV infected axolotl cells. G. LV
infected axolotl cells. H. Phase contrast image of culture from G. Scale Bars: 200 μm.
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of reverse transcribed HIV genomes actively imported
into the nucleus of cells infected during interphase and
resulting in expression from episomal vector DNA ge-
nomes. The subsequent decline within the first 3 weeks
after transduction may then be a consequence of ineffi-
cient viral integrase-mediated LV vector insertion into
the host genome. In contrast, FV vectors are known to
require mitosis for access to host chromatin and can res-
ide in a latent state at the centrosome of non-dividing
cells for weeks [18,19]. Thus, an increase of the percent-
age of EGFP expressing cells within the first 3 weeks
after transduction might be the result of efficient inte-
gration of FV vector genomes only after individual mi-
totic divisions of individual cells. For the majority of
target cells this might take up to three weeks.
We next wanted to test the ability of the viruses to
infect limb tissue in vivo. Concentrated virus prepara-
tions were prepared by centrifugation and subsequently
injected in mature limbs of axolotls. We did not observe
any EGFP labeling in these limbs injected with LV or FV
particles (data not shown). Since FV require mitosis to
access their host genome, we injected LV and FV parti-
cles into 5 day old axolotl forelimb blastemas. Injection
of 0.5 to 2 μl of concentrated FV particles (titer of
1.44×108 IU/ml) consistently yielded labeling of many
limb cells (Figure 3A). To test the stability of transgene
expression, we allowed the limbs to fully regenerate and
then re-amputated the limbs. After 5 weeks of second
round regeneration, we continued to observe robust ex-
pression of EGFP (Figure 3B). Similarly, tail and limb
Figure 3 In vivo infection of regenerating limbs with foamy versus lentivirus vector particles. Concentrated FV or LV vector particles were
injected into 5-day limb blastemas, which were then allowed to regenerate. Images were taken 28 days post-injection. A. FV vector particle
(EGFP) injected limb. B. FV vector particle injected limb that had regenerated, and then was reamputated and regenerated a second time
showing stability of expression. C. FV vector particle (DsRed) injected limb. D. FV vector particle (DsRed) injected tail. Asterisk point to labeled
blood vessels. The inset shows high magnification of the fin where blood vessels are labeled. E, F. LV vector particle (EGFP) injected limb in bright
field (E), and fluorescence (F) shows no fluorescence signal. Scale Bars: A,C: 500 μm B,D,E,F: 1 mm.
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blastema were injected with FV particles containing
UBIC promoter driving DsRed and allowed to regenerate
(Figure 3C, D). In contrast, we observed virtually no
gene expression after injection of a similar volume of
the highest concentration LV preparations that we could
achieve (titer of 1.02×108 IU/ml) (Figure 3E, F).
To determine the specific cell types that were labeled we
cross sectioned the infected, regenerated limbs and
performed immunostaining. We observed EGFP/DsRed
expression that co-localized with immunostaining for
muscle specific myosin (muscle), collagen (cartilage), kera-
tin (dermis), myelin basic protein (Schwann cells and
nerve tracts) and blood vessels (Figure 3D, Figure 4).
To ascertain the efficiency of FV to transfer two genes
(via two separate foamy viruses), A1 cells were trans-
duced with a mixture of FV (EGFP and DsRed). We saw
colocalization of both the fluorescent proteins in major-
ity of cells (Figure 5A). Similarly, colocalization of EGFP
and DsRed was also observed in nerve tracts of spinal
cord when a tail blastema was injected with the two FV
viruses (Figure 5B). These results confirm that multiple
FV particles can transfer genes in the same target cell.
To determine if viral transduction could be used to
achieve cell type-specific expression, we inserted the
CarAct:EGFP expression cassette (muscle specific pro-
moter driving EGFP) into a FV vector and produced
concentrated vector stocks as described in methods and
materials. Subsequently, vector particles were injected in
blastemas at day 5 and regeneration was allowed to
occur. We observed EGFP expression only in the limb
muscle fibers in the regenerated limb and not in any
other cell type (Figure 5C-F). Therefore, foamy virus
vector-mediated transgene integration results in faithful,
cell-type restricted expression.
These results indicate that FV particles can infect blas-
tema cells with stable and persistent expression during
regeneration and after amputation. Furthermore, tissue
specific expression is achieved when combined with tis-
sue specific promoter. FV vectors have previously been
shown to transduce cells from species very distantly re-
lated to their natural hosts [12,13,15]. Electroporation of
plasmid DNA has been successfully established in sala-
manders but it cannot be used for experiments that re-
quire long-term gene expression as electroporated DNA
is episomal and dilutes out during cell division. Similarly,
establishing germline transgenic axolotls is a tedious
process requiring 12-15 months (Khattak et al; Stem Cell
Reports-in press). The results of this study show that FV
vectors are an effective gene delivery tool for non-
mammalian models, such as the salamander, resulting in
long-term transgene expression. Interestingly, not only
in vitro but also in vivo, their efficiency and the stability
of transgene production was superior to the currently
most favored retroviral vector system based on
lentiviruses pseudotyped by the glycoprotein of the rhab-
dovirus VSV. Availability of foamy virus gene transfer
system together with recently reported psuedotyped
retrovirus [8] for regeneration research, such as the axo-
lotl/salamander system, will greatly expand the ability to
test gene function during regeneration.
Conclusions
We here report on the successful application of foamy
virus as a vector for transgene integration and sustained
expression during regeneration. Upon infection of the
blastema, EGFP expression was observed in multiple cell
types, and expression lasted throughout regeneration
and persisted through a second round of regeneration.
Both limb and tail blastema were transduced with foamy
virus expressing EGFP/DsRed and resulted in wide range
of cells labeled after limb/tail regeneration was complete.
We also demonstrated the compatibility of this system
with cell-type specific expression by incorporating the
Xenopus cardiac actin promoter in the foamy virus vec-
tor. Our observation of widespread and stable expression
with the foamy virus contrasts with the difficulty to
achieve persistent in vivo transgene expression with con-
centrated lentivirus vectors.
Methods
Cells and culture conditions
The human kidney cell line 293T [20] and the hu-
man fibrosarcoma cell line HT1080 [21] were culti-
vated in Dulbecco’s modified Eagle’s medium (DMEM)
supplemented with 10% heat-inactivated fetal calf serum
and antibiotics. The newt myogenic cell line A1 [17]
was cultivated in 70% Eagles minimal essential media
supplemented with 10% fetal bovine serum, insulin and
penicillin/streptomycin.
Expression constructs
For this study a replication-deficient expression-opti-
mized 4-plasmid vector system based on prototype FV
(PFV) recently developed by our laboratory was used
[22] (Figure 1A). It comprises three packaging plasmids
containing expression-optimized ORFs for the PFV cap-
sid precursor protein Gag (pcoPG4) [15], the PFV en-
zymatic precursor protein Pol (pcoPP) as well as the
PFV glycoprotein precursor Env (pcoPE) [22] and the
transfer vector puc2MD9 Ubi WPRE [15]. The transfer
vector contains the minimal essential cis-acting viral
sequences [7] that are required for vector RNA and
enzyme (Pol) encapsidation as well as vDNA synthesis
and its integration into the host cell genome mediated
by the pol-encoded viral reverse transcriptase and
integrase, respectively. With FVs having one of the lar-
gest viral genomes (~12 kb) the PFV transfer vector can
accommodate up to 9 kb of non-viral genetic material
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[23]. All packaging plasmids are based on the pczi ex-
pression vector, a pcDNA3.1+ variant containing an
hCMV intron A sequence resulting in the expression of
spliced mRNAs [24]. Expression-optimization and gene
synthesis of the PFV ORFs was performed at Geneart
and enables production of vector supernatants with 5-10
fold higher titers than achieved with FV vector systems
based on authentic viral sequences [22,24,25]. The
puc2MD9 Ubi WPRE transfer vector used in this study
is a variant of puc2MD9 published previously having the
original SFFV U3 promoter driving EGFP or DsRed
marker gene expression replaced by a human ubiquitin
C promoter (hUbiC) [15]. Furthermore the WPRE post-
transcriptional active element was inserted downstream
of the EGFP gene.
For generation of replication-deficient lentiviral vec-
tors a 3-plasmid system was used (Figure 1B). It consists
of two packaging plasmids, pCD/NL-BH [26], encoding
HIV-1 Gag/Pol as well as some accessory proteins;
pczVSV-G [27], encoding the vesicular stomatitis virus
glycoprotein (VSV-G); and the HIV-1 transfer vector
p6NST90 [15]. p6NST90 is a variant of p6NST50 [28]
having the SFFV U3 driven IRES EGFP-Zeo expression
cassette replaced by a hUbiC promoter driven EGFP/
DsRed cassette. Details on the construction of the vec-
tors are available on request.
Generation of viral supernatants
FV supernatants containing recombinant viral particles
were generated essentially as described previously
[25,29]. Briefly, FV supernatants were produced by
polyethyleneimine (PEI)-mediated cotransfection of
293T cells with transfer vector (e.g. puc2MD9 Ubi
WPRE), Env- (pcoPE), Pol – (pcoPP), and Gag packaging
plasmid (pcoPG4) at a ratio of 28:1:2:4 using 16 μg total
DNA per 10-cm dish. At 32 h post transfection the
medium was replaced, and cell-free viral supernatants
were harvested by sterile filtration (0.45 μm pore size)
an additional 16 h later. Supernatants were used directly
or aliquots snap frozen on dry ice and stored at -80°C
until further use. Lentiviral supernatants were generated
by cotransfection of transfer vector (p6NST90), Gag/Pol
packaging plasmid (pCD/NL-BH), and an Env packaging
plasmid (pczVSV-G) at a ratio of 1:1:1 and harvested as
described above. For in vivo transduction experiments
vector particles were concentrated from cell-free viral
supernatant by ultracentrifugation for 1.5 h at 25,500
rpm using a SW28 rotor (35 ml supernatant per bucket).
Pelleted vector particles were gently resuspended on ice
in PBS with 0.1 % BSA and aliquots were snap frozen
and stored in – 80°C until use. Recovery of lentiviral
VSV-G pseudotypes was generally above 70% and of
PFV vector particles above 50%.
Analysis of in vitro and in vivo transduction efficiency
Infectious titers used for calculation of multiplicities of
infection (MOI) were determined on HT1080 cells. In
vitro transductions of recombinant EGFP expressing FV
or HIV-1 vector particles were performed by infection of
2 × 104 HT1080 cells, plated 24 h in advance in 12-well
plates or by infection of 2 × 104 A1 cells, plated 48 h in
advance in 6-well plates. For the infection 1 ml
(HT1080) or 1.5 ml (A1) of the viral supernatant or dilu-
tions thereof were incubated with the target cells for 8 h.
The percentage of EGFP-positive cells was determined
by fluorescence-activated cell sorter (FACS) analysis at
different time points after infection, as indicated. For
double infections, DsRed and EGFP viruses were mixed
before putting them on A1 cells as indicated above. All
transduction experiments were performed in triplicates
and at least three times.
For in vivo infections, 2-3 cm axolotl larvae were used.
The animals were bred and raised in our colony and
kept in local tap water at 18°C. The larvae were fed with
freshly hatched brine shrimps (Artemia) every day. All
animal procedures were done according to the animal
and biological safety level 2 (S2) license (24D-9168.11-
9-2006-1 and 55-8811.72/34-16) issued by “Regierung
spräsidium Dresden” and “Sächsisches Staatsministerium
für Umwelt und Landwirtschaft (SMUL)” respectively.
The ethical approval was obtained from the "Landes
direktion" for animal welfare for the State of Saxony.
(See figure on previous page.)
Figure 4 Foamy virus vector transduce muscle, cartilage, dermis, Schwann cells in the regenerating axolotl limb and tail. A. Cross
section of limb shown in Figure 3C (transduced with FV-DsRed) showing wide spread DsRed expression. B. Cross section of tail shown in
Figure 3D (transduced with FV-DsRed) showing wide spread DsRed expression. Arrow points to the spinal cord. C. Immunofluorescence staining
for muscle specific myosin heavy chain (MHC) in limb (transduced with FV-DsRed) showing endogenous DsRed expression (left), MHC staining
(middle) and merged of the two images is shown on the right. (DAPI=blue). D. Immunofluorescence staining for collagen in limb (transduced
with FV-EGFP) endogenous EGFP expression is on the left, collagen staining (middle) and merged of the two images is shown on the right.
(DAPI=blue). E. Immunofluorescence staining for keratin in tail (transduced with FV-DsRed). The image shown is a blow up of the tail fin region
showing excellent colocalization of endogenous DsRed expression (left) with keratin immunostaining (middle). F. Immunofluorescence staining
for myelin basic protein (MBP) in tail (transduced with FV-DsRed). The image depicted here shows the spinal cord and associated peripheral
nerve tracts showing endogenous DsRed expression (left), MBP staining (middle) and merged of the two images on the right. Scale bars: A:
100 μm, B: 200 μm, C,E,F: 20 μm, D: 10 μm.
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Before every animal procedure, animals were anes-
thetized in 0.01% ethyl-p-aminobenzoate (benzocaine;
Sigma). For each experiment, lower forelimbs or tails of
nine animals were amputated and animals were
returned to fresh water in separate boxes for blastema
induction. After five days, 5 day blastemas were injected
with 0.5 – 2 μl of concentrated foamy and/or lentivirus
with help of glass capillaries (Harvard Apparatus) pulled
by using a Sutter Flaming Brown P-97 puller to a tip size
of approximately 1–2 μm and injected using PV830
Pneumatic PicoPump (WPI). The transduced animals
were kept on a wet tissue for 20 min before putting
them in fresh water, which was changed every second
day. EGFP/DsRed fluorescence was first observed 7-8
days post infection. Amputation of limbs and detection
of fluorescence was performed on Olympus SZX16
stereomicroscope. All transduction experiments were
repeated three times.
Figure 5 Multiple genes transfer and tissue specific expression via foamy viruses. A. EGFP and DsRED expression is seen in A1 cells
transduced with mixture of EGFP and DsRED foamy viruses. A’. untransduced A1 cells. B. Cross section of tail showing spinal cord and
surrounding nerve tracts. Tail blastema was transduced with mixture of FV containing DsRed and EGFP FV particles. Colocalization is seen
between EGFP and DsRed fluorescent signal.C-F. Muscle-specific expression was achieved when FV vector particles harboring the Xenopus
CarAct:EGFP cassette were injected into the blastema at day 5 after amputation of a 3 cm larvae. C. Cross section of limb showing EGFP
expression in muscle tissue. D. MHC immunostaining of section to highlight muscle cells/fibers. E. PAX7 immunostaining of same section to
delineate satellite cells. F. Overlay to show that GFP signal is exclusive of PAX7+ satellite cells. Scale bars: A,A’: 200 μm, B: 20 μm, C-F: 50 μm.
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Immunohistochemical analysis of transduced
re-regenerated limb tissue
Regenerated limbs were amputated 28 days post infec-
tion to harvest the limb tissue. The cut part was fixed in
1% MEMFA for 4 hrs at RT followed by three washes of
PBS and then incubated overnight at 4°C in 30% sucrose.
The next day, tissue was embedded in Tissue-Tek
(OCT compound-Sakura), cryosectioned and slides were
allowed to dry at RT for 1-2 hrs. Limb and tail sections
were washed 3 times with PBS-Tween (0.3%) and
blocked for one hour with 2% BSA, 5% normal serum
and 0.3% Triton-X (blocking solution), followed by
overnight incubation with the primary antibody diluted
in blocking solution. Primary antibodies used were
anti-PAX7 mAB (Developmental Studies Hybridoma
Bank), anti-MHC (monoclonal antibody 4A1025 kindly
provided by S. Hughes), mouse anti-chicken collagen
Type II antibody (Millipore) and monoclonal anti-Pan
Cytokeratin antibody mixture (Sigma). After several
washes with PBS-Tween, sections were then incubated
for 1 hour with respective secondary antibodies and
Hoechst solution for nuclear staining. Images were taken
on Leica confocal microscope and Zeiss Observer.
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